Mounjaro and Hair Loss: NHS Guidance, the Real Cause, and What Helps

The myth: Mounjaro is damaging your hair follicles

This is the version of events that circulates on forums, and it is largely wrong. Hair loss appears in Mounjaro's patient information leaflet as an uncommon reported event, but clinical context matters here. The leading explanation (supported by the pattern seen in SURMOUNT trials and by broader NHS experience with significant weight loss) is telogen effluvium. Your body, interpreting rapid weight change or reduced calorie intake as a form of physiological stress, shifts more hair follicles into the resting (telogen) phase simultaneously. Weeks later, they shed together.

Tirzepatide itself is not known to have a direct toxic effect on hair follicles. The NHS notes this same pattern with bariatric surgery, crash dieting and other major calorie deficits. So if you are losing hair at month three or four of treatment, the weight loss is the more likely culprit. That is genuinely useful to know, because it changes what you do about it.

Check your plate before you check your pen. A quick way to start: look at how much protein you are eating in a typical day. On GLP-1 treatment appetite drops sharply, and people frequently under-eat protein without realising it, 1–1.2g per kilogram of body weight per day is a commonly cited target, though your prescriber or a dietitian can advise what is right for you personally.

What the NHS and clinical evidence actually say

The NHS tirzepatide medicines page lists hair loss among uncommon side effects, meaning it may affect up to 1 in 100 people. The MHRA's monitoring, reinforced by post-marketing data reported through the Yellow Card scheme, does not identify hair loss as a serious safety signal for tirzepatide specifically, it is flagged for completeness, not as a frequent harm.

Telogen effluvium typically peaks 3–4 months after the triggering event and resolves within 6–9 months as the body adapts. Hair density returns for most people once weight loss slows and nutritional status improves. This does not mean you should ignore it or push through discomfort alone, but the prognosis is generally reassuring.

For context on how the NHS frames weight-loss medicines more broadly, the NHS England guidance on weight-management injections is a sound starting point. It covers what to expect across the treatment journey, including guidance on diet, lifestyle support and when to contact your clinical team. If you are also considering how NHS access to tirzepatide works, our page covering the weight loss jab Mounjaro on the NHS sets out the current eligibility and rollout picture, and our NHS Mounjaro weight loss page goes further into what the programme covers and what outcomes patients can expect.

When you should get medical help

Most Mounjaro-related hair shedding is diffuse, general thinning across the scalp rather than patches. The following warrant a prompt conversation with your GP or prescriber, rather than a watchful wait:

Patchy hair loss, bald spots or defined areas of loss may suggest alopecia areata or another condition unrelated to your weight-loss treatment. Loss that started before treatment or continues past 6 months without any sign of slowing may have a separate cause: thyroid dysfunction, iron deficiency and low ferritin are common culprits that a simple blood test can identify. Significant loss alongside scalp irritation, pain or skin changes also needs assessment. None of these are emergencies, but none should sit unchecked for months either.

If you suspect a side effect from tirzepatide is contributing, reporting it directly through the Yellow Card scheme helps the MHRA's ongoing safety monitoring. You do not need to be a healthcare professional to file a report, the link is yellowcard.mhra.gov.uk. Reports from patients are taken seriously and contribute to the evidence base that shapes future guidance.

What practically helps, and how nume (sorry, how a clinical review) can support you

Practical steps that align with NHS and dietitian advice for people experiencing telogen effluvium during weight loss: prioritise protein at every meal (eggs, fish, pulses, Greek yoghurt); maintain iron intake from food or supplements if blood tests support it; keep hydrated; and consider a broad micronutrient check if hair loss is significant. Biotin supplements are widely marketed but the evidence for them in people without a diagnosed biotin deficiency is thin. Save the money and spend it on protein-rich food.

Slowing your rate of weight loss, if your prescriber considers this appropriate, can also reduce the physiological stress on hair follicles. This is not a reason to stop treatment, abrupt discontinuation carries its own risks and requires a clinical conversation. Our prescribers at nume review this as part of ongoing care, not as a one-off consultation. Questions about Mounjaro's side-effect profile, dosing context and whether treatment is right for you are covered as standard during the initial assessment. You can read more about the treatment options available through our free consultation page, or explore the broader picture on our Mounjaro overview. The safety overview for Mounjaro on the NHS also addresses common questions about how this medicine's risk profile has been assessed. Separately, if cost or access is part of your thinking, our guide to buying research tirzepatide explains what distinguishes that route from a legitimate private prescription service, and our Mounjaro pricing context page explains what a legitimate private prescription service includes.